CTIX recent news/filings/charts etc.
## source: finance.yahoo.com
Tue, 09 Sep 2014 19:00:00 GMT ~ Cellceutix Provides Initial Observations of Completed ABSSSI Phase 2b Trial; Company Submits Investigational New Drug Application to FDA for Phase 2 Trial of Brilacidin-OM for Oral Mucositis
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce this update on its recently ...
read full: http://finance.yahoo.com/news/cellceutix-provides-initial-observations-completed-190000867.html
*********************************************************
Fri, 05 Sep 2014 15:15:46 GMT ~ Cellceutix to Present at Rodman & Renshaw's 16th Annual Global Investment Conference
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announced today that Leo Ehrlich, CEO will be ...
read full: http://finance.yahoo.com/news/cellceutix-present-rodman-renshaws-16th-151546102.html
*********************************************************
Tue, 02 Sep 2014 11:00:00 GMT ~ Cellceutix Appoints Dr. Barry Schechter to Board of Directors as Company Focuses on Meeting Requirements for Stock Exchange Uplisting
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce the appointment of Dr. ...
read full: http://finance.yahoo.com/news/cellceutix-appoints-dr-barry-schechter-110000360.html
*********************************************************
Tue, 02 Sep 2014 10:29:26 GMT ~ CELLCEUTIX CORP Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statements and
read full: http://biz.yahoo.com/e/140902/ctix8-k.html
*********************************************************
Tue, 19 Aug 2014 12:30:00 GMT ~ Cellceutix Completes Enrollment in Phase 2b Clinical Trial of Brilacidin for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, has announced the completion of enrollment in ...
read full: http://finance.yahoo.com/news/cellceutix-completes-enrollment-phase-2b-123000703.html
*********************************************************
$CTIX charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$CTIX company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/CTIX/company-info
Ticker: $CTIX
OTC Market Place: OTCQB
CIK code: 0001355250
Company name: Cellceutix Corp.
Company website: http://www.cellceutix.com
Incorporated In: NV, USA
Business Description: An early stage developmental biopharmaceutical company...with six pharmaceutical compound candidates that are designed for treatment of diseases which may be either existing or diseases identified in the future. The Company will initially spend most of its efforts and resources on its anti-cancer compound, Kevetrin, for the treatment of head and neck cancers.
$CTIX share structure
## source: otcmarkets.com
Market Value: $225,776,700 a/o Sep 12, 2014
Shares Outstanding: 108,027,129 a/o May 07, 2014
Float: Not Available
Authorized Shares: 300,000,000 a/o May 12, 2008